Skip to main content
Premium Trial:

Request an Annual Quote

Transgenomic Shares Slide 5 Percent on News of CEO Departure

NEW YORK, April 4 (GenomeWeb News) - Shares of Transgenomic were down 5.63 percent, or $.04, at $.67 in mid-afternoon trading after the company said CEO Collin D'Silva has resigned.

 

As GenomeWeb News reported this morning, Michael Summers, the company's chief financial officer, has taken over as interim CEO until a new chief executive has been found. He also remains CFO.

 

D'Silva will remain chairman of the board and will manage "strategic customer relationships" and evaluate corporate strategic alternatives.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.